COVID-19: Human Subjects

Go to the IRB homepage

 

Updates on COVID-19: Human Subjects (IRB)

As on-campus research related activities gradually ramp up, and as Pennsylvania counties begin “moving to green,” the Office for Research Protections would like to remind researchers that on-campus research is either in Research Phase 2 or Phase 3 (out of 5), depending on the campus location and on whether the corresponding dean, institute director, or chancellor has an approved plan. Researchers should review Penn State’s phases for gradually returning to on-campus research, which were announced by the Senior Vice President for Research on May 19, 2020. Although aligned with Pennsylvania’s phases, Penn State’s Return to Research Phases are separate and distinct from the Commonwealth’s color-coded phases and are moving at a different pace. 

Research Phases 2 and 3

Research Phase 2 is a transition phase in which unit leaders (deans, chancellors, and institute directors) create a prioritized and phased list of research-related activities that are expected to increase on campus. Unit leaders must approve all on-campus research activities within their respective units at each Research Phase. Some units have completed Research Phase 2 and transitioned to Research Phase 3. Researchers are not allowed to return to on-campus research without approval from their Unit Leader in coordination with OSVPR. Researchers should communicate with their unit leaders for unit-specific information. In Phase 2 of the Return to Research plan, with some exceptions, human subjects research must occur remotely. In Phase 3 of the Return to Research plan, with some exceptions, human subjects research must continue to occur remotely. 

Revised Standards for Human Subjects Research

In addition to the Return to Research Phases, the OSVPR has updated the Revised Standards for Human Subjects Research. The Revised Standards apply to Penn State human subjects research, regardless of location, including international sites. For allowable face-to-face research, principal investigators must be aware of any local restrictions and required safety protocols (e.g., hospital-specific requirements, county- or state-level ordinances, etc.). The Revised Standards will continue to be updated as circumstances change.

This webpage addresses COVID-19-related questions as pertains the Penn State's IRB programs (Office for Research Protections and Human Subjects Protection Office). Penn State Health researchers and staff should also view Penn State Health-specific guidance. See the Penn State COVID-19 webpage for University updates.

Last updated June 1 with updates to Research Phases. Previously updated May 29 with revised Standards and FAQs.

 

Information on the Revised Standards

Revised standards for human subjects research 

  • In the context of rapidly evolving circumstances regarding COVID-19, and the University’s focus on social distancing and the health and well-being of the community, the Revised Standards for Human Subjects Research were updated May 29, 2020, by the Office of the Senior Vice President for Research, in consultation with the Vice Dean for Research and Graduate Studies in the College of Medicine. The Revised Standards will be updated as circumstances change. Initiation of all on-campus research must be approved by unit leaders following University guidance. Research visits should continue to be performed remotely (e.g., by phone or Zoom) whenever possible. 
  • ORP/HSPO IRB offices will prioritize modifications related to COVID-19.  
  • All modifications to research procedures require IRB review and approval prior to implementation, except those that are necessary to eliminate an immediate apparent hazard to a participant (these are then required to be submitted to the IRB afterward as an RNI).

Penn State Health observational studies

Effective June 1, 2020: When in Research Phase 3, observational studies at Penn State Health (inpatient and outpatient) locations may resume under the following conditions (must follow guidelines):

  • The subject will be present on campus for a clinical reason (either outpatient clinical visit or inpatient hospitalization or procedure).
  • Approval has been obtained to recruit patients for the specific study in writing (via email) from the medical director of the unit.
  • Use of PPE (mask, gowns, face shields, etc.) follows practices of good stewardship as outlined by Penn State Health.
  • All studies and study changes have IRB approval. 

See page 3 of Revised Standards for Human Subjects Research for additional guidelines for research visits.
 

 

Study location, including international research 

The Revised Standards apply to Penn State research, regardless of location. Research without direct drug or device therapeutic benefit can only continue if the research is conducted remotely. This includes international sites.

For allowable face-to-face research, PIs must be aware of any local restrictions and required safety protocols (e.g., hospital-specific requirements, county- or state-level ordinances, etc.).

 

Voluntary research pause

The PI may decide to voluntarily pause, delay, or reschedule interactions with subjects because of COVID-19 ; in such cases, there is no need to inform the IRB, regardless of review level. This is a temporary change to the IRB’s policy regarding submission of an RNI in these situations specifically related to the impact of COVID-19. However, you must:

  • ensure the voluntarily pause does not increase any risk to study subjects if the your study is a greater-than-minimal risk study that involves some type of patient care.
  • contact study subjects who will be affected by this suspension (e.g., a study visit will be cancelled, etc.).

Investigators should notify the study sponsor and any others necessary, as required.

Investigators are required to document the voluntary pause in the study records along with the justification and any actions taken in the event that this is needed during an audit.

Modifying visits from in-person to remote/virtual 

  • Changes to move from in-person study visits to virtual/remote or phone options must be approved in advance by the IRB as a modification to the approved study. Exempt studies do NOT need to submit a modification unless the change would alter the review level of the study, as per the Investigator Manual.
  • ORP/HSPO IRB offices will prioritize modifications related to COVID-19.  
  • All modifications to research procedures require IRB review and approval prior to implementation, except those that are necessary to eliminate an immediate apparent hazard to a participant (these are then required to be submitted to the IRB afterward as an RNI).
  • IRB analysts are available to discuss moving a study from face-to-face to remote interactions. Please contact your IRB analyst with questions, or email ORP: IRB-ORP@psu.edu HSPO: hspo@pennstatehealth.psu.edu.

Modifying consent forms

Consent forms do not need to be revised if the revised procedures do not introduce new or increased risks. When submitting modifications for procedures, IRB staff are evaluating whether changes to the consent are necessary.

 

 

Important notes for modifications to perform research remotely

When submitting a modification, please note in the submission to the IRB that the PI is adding the option to perform research remotely under the COVID-19 revised standards for human subjects research. Include in the modification that once in-person research is allowed again, the study will return to previously approved procedures.  (Doing so will eliminate the need to submit another modification later when/if the PI wishes to resume normal study activities.)

In the modification, please consider and address the following, where applicable:

  • Potential impact on subject safety and protections
  • Potential privacy and confidentiality concerns.
  • Data security requirements and obtaining IT security approval.
  • Explain how recordings are to be made remotely. Non-Penn State Health investigators: Zoom is a viable option for Level 1 and Level 2 data; for Level 3 and 4 data, contact Office of Information Security Security@psu.edu. Please note the non-Penn State Health Zoom is NOT HIPAA compliant for storing Level 3 or Level 4 data.  
  • Potential impact on scientific integrity and/or benefits of the study
  • Plan for how existing subjects will be notified (if their participation will be affected by the Modification)

Information on how to submit a modification to an approved study can be found at https://www.research.psu.edu/irb-modification.

Modifications that cannot wait for IRB approval

If it is in the best interest of the subject to eliminate an immediate apparent hazard to one or more participants and there is no time to obtain prior IRB approval, a researcher may do so. The PI must then submit this modification as reportable new information (RNI) within 5 business days to the IRB for review.

Sponsor changes to a study

If a sponsor provides sites with guidelines for conducting the research study, a modification request must be submitted. The Modification Summary must indicate that the modification request is to disclose sponsor correspondence due to the COVID-19 pandemic; upload the sponsor documentation on the Basic Information page.

Also, the site-specific section of HRP-595 must be updated to include the alternate process(es) that the site will follow based on the sponsor’s guidance document. The PI should be sure to indicate that these processes will be followed only during the PSH/PSU/COM Revised Standards for Human Subjects-Related Research Visits during COVID-19. Note that the site will return to the usual process(es) when the revised standards are removed by PSH/PSU/COM. Adding this wording provides a definitive end-point that will be University wide, thereby removing the requirement to submit a modification request to the IRB to return to the usual process with the revised standards are removed.

If sponsor’s guidance provides optional processes to follow, only the processes the site with actually follow must be included in the revised HRP-595. If the entire sponsor guidance document contains only optional processes and the site chooses to not follow any of the processes, indicate this on the Modification Summary and do not revise HRP-595. 

Consent forms do not need to be revised if the revised procedures do not introduce new or increased risks. When submitting modifications for procedures, IRB staff are evaluating whether changes to the consent are necessary.

Studies using Doximity

If your study procedures already involved phone calls and you are now using Doximity to make those phone calls, you do NOT need to make any changes to any of your documents.  

If you are now performing phone calls in lieu of in-person visits or adding additional phone calls, you need to update your protocol documents (HRP-591, HRP-595, etc, -- depending on the type of research) to reflect this. 

If you were not collecting phone number prior to the change, you will also need to update HRP-598 to indicate that phone number will be stored. 

 

Reportable New Information (RNI) for a sponsored study

For changes to subject visit or enrollment procedures (new COVID-19 procedures), submit a modification to the HRP-595.

Submit RNI for sponsored study for the scenarios listed below. The IRB is prioritizing these reviews and acknowledging daily.  

  • Sponsor recommendations and guidance during COVID-19, received by study teams: 

    • Suspending or holding enrollment (Note: if no subjects are enrolled, this does not necessitate any further actions by the site)
    • General notifications to sites
  • A process was altered prior to IRB approval to eliminate an immediate or apparent hazard to one or more of the participants and there is no time to obtain IRB approval.

 

Participant safety monitoring

For clinical studies requiring in-person study visits in order to conduct safety monitoring of the participants, researchers should plan for alternatives to in-person monitoring visits, if possible. For example, interviews could be conducted by phone or email or perhaps the schedule of monitoring could be safely modified or delayed. Modifications to safety monitoring procedures should be approved in advance by the IRB, except when necessary to eliminate apparent hazards to a participant and there is not sufficient time to obtain IRB approval.

If a PI does need to change an approved monitoring procedure to eliminate immediate possible danger, please report it to the Penn State IRB within 5 business days, following the Reportable New Information (RNI) procedures described in the Investigator Manual (HRP-103) on page 52. 

Information for Researchers Planning COVID-19 Research

Notifying the IRB of a new study or modification related to COVID-19

To ensure timely processing of submissions related to COVID-19, we ask that the researcher identify a submission in the following way:

New Study Submission:

  • Include COVID-19 in the short title (question #2 in the short form)

Reportable New Information (RNIs):

  • Include COVID-19 in the RNI short title (question #1)

Modification:

  • Use the “Add Comment” feature in CATS IRB to add “COVID-19” as a comment to your submission and check “IRB Coordinator” under item #3 in the pop up box. Note: The “Add Comment” button is found left side of the screen on the main study workspace in CATS IRB. 

Failure to identify a submission as outlined above may result in delays in review.

COVD-19 research and specimens 

Research on COVID-19 is evaluated on a case-by-case basis. If a PI is working with materials related to Covid-19/SARS-CoV-2/Coronavirus, the Institutional Biosafety Committee strongly recommends researchers review the CDC’s guidelines daily to ensure the lab is meeting the latest safety standards. Note, it is possible that some materials can be ordered at BSL 1 but are now being handled at BSL 2 per the CDC’s guidance. Please contact the IBC Email prior to initiating work and/or if you have any additional questions. Resource Links: IBC Applications, CDC’s Website & ABSA International Website

For Penn State Health: Due to biosafety concerns, and in conjunction with the CDC recommendations for specimen handling from COVID-19 patients, any study that aims to enroll COVID-19 subjects will require a modification to the protocol for IRB approval, which will include a biosafety review. COVID-19 patients cannot be enrolled on existing protocols without this modification approved. 

 

COVID-19 related activities that are not human subjects research

 Penn State is ready to assist researchers and clinical care providers who are planning COVID-19-related activities that may intersect or overlap with public health authority activities and/or FDA emergency authorizations for diagnostics. In some cases, IRB approval will not be required. Penn State can assess the circumstances, provide advice, and issue determination letters (if warranted).  

The procedures for a single patient emergency use of an investigational drug or device remains unchanged during this time. The policy for Emergency Use of an Investigational Drug or Device is on the HSPO website. Read about the FDA Guideline.

Other Frequently Asked Questions

Yes. Even if the research is paused for the time being, the PI must still submit the Continuing or Administrative Review to ensure that the study stays active. This will allow research to begin again immediately when appropriate and/or permitted. Failure to submit will result in study closure. If the study is closed, the study cannot be re-opened and all human research activities must stop.

Studies registered at the federal site ClinicalTrials.gov that are modifying their research procedures to include testing for SARS-CoV-2 and/or assessment of COVID-19 symptoms should update the ClinicalTrials.gov information to include these new procedures, if they are done for research purposes. If new procedures are being added as public health surveillance activities in coordination with public health authorities, the registration information does not need to be modified. Any research-related changes that are communicated to the subjects (past, ongoing, future) must be added to the study’s ClinicalTrials.gov registration with 30 days after IRB approval of the modification.

In those cases where research visits must be postponed (i.e., cannot be performed remotely and are not essential to a participant's health and have a direct therapeutic benefit) and graduate student researchers are involved whose research for their degree will be impacted, faculty/investigators should work with their students to develop revised/alternative plans to enable continued progress towards their degree. Read more from the graduate school: http://gradschool.psu.edu/covid19/.

The Office for Research Protections (ORP) at University Park and the Human Subjects Protection Office (HSPO) at the College of Medicine, including the IRBs, are fully operational. Staff are working remotely and most meetings are being held virtually. If you plan to visit the office in-person, please make arrangements in advance. Staff are happy to arrange Zoom meetings or conference calls with researchers as needed. All ORP and HSPO email addresses and phones continue to be monitored with the same or greater frequency, however, responses to inquiries and applications that are not related to COVID-19 or its impact on research may be delayed somewhat. This website will remain the best source of information during this time; please plan to check back often.

Highest priority is being given to all inquiries, requests, applications, and modifications related to SARS-CoV-2 or COVID-19.  

For more information, contact your IRB analyst or the IRB office (Penn State Health and College of Medicine: hspo@pennstatehealth.psu.edu, Office for Research Protections: IRB-ORP@psu.edu).